Lung cancer is a type of cancer that develops in the lungs, which are the primary organs of our respiratory system and allow us to breathe. The lungs are a pair of cone-shaped organs that are located under our ribcage.
The respiratory system is composed of the nose, mouth, trachea (windpipe) and airways (bronchi and bronchioles) that lead to the lungs, which is where the breathing process primarily occurs. Each lung is made up of lobes, with the right lung being composed of three lobes and the left only having two lobes to accommodate room for the heart. The lungs sit on top of a muscle called the diaphragm, which separates the abdomen from the chest. The diaphragm works by contracting/flattening when we inhale, pulling air into the lungs. When we exhale, the diaphragm relaxes and pushes air out of the lungs. The space between the lungs is called the mediastinum, and holds several important structures, including the heart, trachea, oesophagus and lymph nodes. Each lung is covered by a layer of tissue called the pleura.
Lung cancer is more common in males, and is generally diagnosed over the age of 65. However, anyone can develop this disease.
Types of Lung Cancer
There are two main types of lung cancer, which are categorised by their cellular appearance under the microscope.
Non-small cell Lung Cancer (NSCLC)
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. Cancer cells look larger than regular cells, and may take the form of:
- Adenocarcinoma (cancer arising from mucous-producing cells), which is commonly found in the outer parts of the lungs.
- Squamous cell carcinoma (cancer arising from squamous cells that line organs), which is commonly found in large airways.
- Large cell undifferentiated carcinoma (cancer that is not an adenocarcinoma or a squamous cell carcinoma), which can begin in several parts of the lungs.
This type of lung cancer tends to be less aggressive than small cell lung cancers, and often have lower metastasis rates.
Small cell Lung Cancer (SCLC)
Small cell lung cancer (SCLC), or oat cell carcinoma, is the less common type of lung cancer. Cancer cells often look smaller than NSCLCs, and usually begin in the bronchi. SCLCs are a type of neuroendocrine tumour. SCLCs tend to be more aggressive and have higher metastasis rates.
Paediatric Lung Cancer
In rare cases, lung cancer may be diagnosed in children and adolescents. There are two main types of lung cancers that affect these age groups: pleuropulmonary blastoma and tracheobronchial tumours.
Pleuropulmonary Blastoma
Pleuropulmonary blastoma is the most common type of childhood lung cancer. It often develops in the tissues of the lung and the pleura, but can develop in the organs located in the mediastinum such as the heart, trachea and oesophagus.
Childhood Tracheobronchial tumours
Tracheobronchial tumours are a very rare type of cancer that develop in the lining of the trachea or the bronchi. These types of cancers most commonly occur as a carcinoma, but may also appear as a inflammatory myofibroblastic tumour, rhabdomyosarcoma or a granular cell tumour.
Some information regarding types of lung cancer was obtained from the Childhood Tracheobronical Tumours (PDQ) and Pleuropulmonary Blastoma (PDQ) pages, which were published by the National Cancer Institute.
Treatment
If lung cancer is detected, it will be staged and graded based on size, metastasis (whether the cancer has spread to other parts of the body) and how the cancer cells look under the microscope. Staging and grading helps your doctors determine the best treatment for you.
Cancers can be staged using the TNM staging system:
- T (tumour) indicates the size and depth of the tumour.
- N (nodes) indicates whether the cancer has spread to nearby lymph nodes.
- M (metastasis) indicates whether the cancer has spread to other parts of the body.
This system can also be used in combination with a numerical value, from stage 0-IV:
- Stage 0: this stage describes cancer cells in the place of origin (or ‘in situ’) that have not spread to nearby tissue.
- Stage I: cancer cells have begun to spread to nearby tissue. It is not deeply embedded into nearby tissue and had not spread to lymph nodes. This stage is also known as early-stage cancer.
- Stage II: cancer cells have grown deeper into nearby tissue. Lymph nodes may or may not be affected. This is also known as localised cancer.
- Stage III: the cancer has become larger and has grown deeper into nearby tissue. Lymph nodes are generally affected at this stage. This is also known as localised cancer.
- Stage IV: the cancer has spread to other tissues and organs in the body. This is also known as advanced or metastatic cancer.
Cancers can also be graded based on the rate of growth and how likely they are to spread:
- Grade I: cancer cells present as slightly abnormal and are usually slow growing. This is also known as a low-grade tumour.
- Grade II: cancer cells present as abnormal and grow faster than grade-I tumours. This is also known as an intermediate-grade tumour.
- Grade III: cancer cells present as very abnormal and grow quickly. This is also known as a high-grade tumour.
Once your tumour has been staged and graded, your doctor may recommend genetic testing, which analyses your tumour DNA and can help determine which treatment has the greatest chance of success. This is often performed after a biopsy, and can help guide treatment options for you.
Genetic testing
Genetic testing (which is also known as genomic testing, genetic panel testing, biomarker testing and/or molecular testing) is the process of analysing the genetics of your tumour to determine which treatment options have the greatest chance of success. These tests often look for genetic mutations, biomarkers (properties of particular cells), environmental factors, or potentially other unknown factors. Understanding the mutations of cancer cells has changed the way cancer is treated, and has resulted in the development of many different treatment options that may be beneficial in the ongoing development of treatments and outcomes for all cancer research.
The most common genetic mutations associated with lung cancer include:
- EGFR (epidermal growth factor receptor).
- ALK (anaplastic lymphoma kinase).
- ROS1 (reactive oxygen species 1).
- KRAS (Kirsten rat sarcoma viral oncogene homolog).
Each of these genes play an important role in regulating/initiating cell growth and division, and so a mutation in these genes may drive abnormal cell growth.
The presence of a genetic mutation may indicate how your tumour will react to certain treatments, and many can be treated by targeted therapies. However, genetic mutations may not always be present in patients with lung cancer. In these instances, your doctor may recommend other treatment options, such as chemotherapy, immunotherapy, or a combination of both.
Treatment options
Treatment is dependent on several factors, including location, stage of disease and overall health.
Treatment options for lung cancers may include:
- Targeted therapies.
- Surgery, potentially including:
- Pneumonectomy (removal of an entire lung).
- Lobectomy (removal of a lobe of a lung).
- Segmentectomy or wedge resection (removal of a portion of a lobe of the lung).
- Radiation therapy.
- Chemotherapy.
- Immunotherapy.
- Home oxygen therapy.
- Clinical trials.
- Palliative care.
Treatment for SCLC does not often include surgery. Due to its aggressive nature, the tumour has often metastasised to other parts of the body, commonly the lymph nodes, before it is diagnosed. In rare cases, where the cancer has been caught early and has not metastasised, surgery may be used to treat SCLC.
For more information on the treatment options, please refer to the Rare Cancers Australia Treatment Options page.
Risk factors
The risk factors for developing any type of lung cancer include:
- Tobacco/cigarette smoking.
- Second-hand or passive smoke.
- Exposure to asbestos.
- Exposure to hazardous workplace substances, such as:
- Radon (radioactive gas).
- Arsenic.
- Cadmium.
- Steel.
- Nickel.
- Diesel.
- Silica.
- Exposure to air pollution.
- Having a family history of lung cancer.
- Having a personal history of any type of cancer.
- Increasing age.
- A history of chronic lung diseases, including chronic obstructive pulmonary disease and pulmonary fibrosis.
Not everyone with these risk factors will develop the disease, and some people who have the disease may have none of these risk factors. See your general practitioner (GP) if you are concerned.
Early symptoms
Early-stage lung cancers may appear asymptomatic, or with a vague set of symptoms. As the tumour progresses, some of the following symptoms may appear:
- Persistent cough (lasting more than a few weeks).
- Coughing or spitting up blood.
- Breathlessness or difficulties breathing.
- Changes in a cough you have experienced for a long time.
- Persistent chest infections.
- Chest and/or shoulder pain.
- Hoarse voice.
- Fatigue.
- Unexplained weight loss.
- Loss of appetite.
- Wheezing.
- Difficulties swallowing.
- Abdominal and/or joint pain.
- Enlarged fingertips (finger clubbing).
Not everyone with the symptoms above will have cancer, but see your GP if you are concerned.
Diagnosis/diagnosing
If your doctor suspects you have lung cancer, they will order a range of diagnostic tests to confirm the diagnosis, and refer you to a specialist for treatment.
Physical examination
Your doctor will collect your overall medical history, as well as your current symptoms. Following this, they may examine your body to check for any abnormalities.
Imaging & blood tests
The doctor will take images of your body using magnetic resonance imaging (MRI), a computed tomography scan (CT scan), x-ray, and/or positron emission tomography (PET scan), depending on where it is suspected the cancer is. The doctor may also look at other parts of the body and looks for signs of metastasis. Additionally, a blood test may be taken to assess your overall health.
Pulmonary function test (PLT)
A pulmonary function test, or lung function test, determines how well your lungs are working. This test measures the amount of air the lungs can hold, as well as airflow in and out of the lungs, how much oxygen is used and how much carbon dioxide is exhaled.
Sputum cytology
A sputum cytology test examines the sputum (or mucus) from your lungs to see if any cancer cells are present. You will be asked to give a sample by coughing deeply and forcefully into a specimen container. Usually, your doctor will ask you collect a sample as soon as you wake up in the morning, as this is when the sputum has been sitting dormant in your throat. This sample will then be sent to a lab and observed for any abnormalities.
Thoracentesis
A thoracentesis, which is also known as a pleural tap or pleurocentesis, is a procedure that drains the fluid from your lungs using a needle. This fluid will then be sent to a lab and analysed for abnormalities.
Exploratory procedures & biopsy
You may require an exploratory procedure may be required if the imaging scans were inconclusive, or if there were any abnormalities detected in your previous tests.
Bronchoscopy
A bronchoscopy is a day procedure that examines the trachea and lungs. A long, thin tube with a light and camera attached (bronchoscope) is inserted through the mouth or nose and into trachea and lungs to check for any abnormalities.
Mediastinoscopy
A mediastinoscopy is a day procedure that examines the mediastinum (area between the lungs). The surgeon will make a small incision in the front of your neck, and insert a long, thin tube with a light and camera attached along the outside of the trachea to check for any abnormalities.
Thoracoscopy
A thoracoscopy is often used if other exploratory procedures have provided inconclusive results. A long, thin tube with a light and camera attached (thoracoscope) is inserted into the chest via a small incision between two of your ribs to check for any abnormalities.
Once the location(s) of the cancer has been identified, the doctor will perform a biopsy to remove a section of tissue using a needle, and can be done during any of the exploratory procedures mentioned above. The tissue sample will then be analysed for cancer cells.
Prognosis (Certain factors affect the prognosis and treatment options)
While it is not possible to predict the exact course of the disease, your doctor may be able to give you a general idea based on the rate and depth of tumour growth, susceptibility to treatment, age, overall fitness, and medical history. Generally, early-stage lung cancers have a better prognosis and survival rates. However, if the cancer is advanced and has spread, the prognosis may not be as good and there may be a higher risk of cancer recurrence. It is very important to discuss your individual circumstances with your doctor to better understand your prognosis.
References
Some references are to overseas websites. There may be references to drugs and clinical trials that are not available here in Australia.